Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications

Laura Cerezo, Higinia Cárdenes, Helen Michael

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Molecular genetic evidence indicates that endometrial carcinoma likely develops as the result of a multistep process of oncogene activation and tumor suppressor gene inactivation. These molecular alterations appear to be specific for Type I (endometrioid) and Type II (non endometrioid) cancers. Type I cancers are characterized by mutation of PTEN, KRAS2, defects in DNA mismatch repair, as evidenced by the microsatellite instability phenotype, and a near diploid karyotype. Type II cancers often contain mutations of TP53 and Her-2/neu and are usually nondiploid. The clinical value of many of these molecular markers is now being tested and it may help to refine diagnosis and establish an accurate prognosis. Furthermore, some of these tumor biomarkers constitute the targets for emerging therapies. Transtuzumab against Her-2/neu and bevacizumab against VEGF overexpressing carcinomas are among the promising novel treatments. Additional translational research is needed to identify molecular and genetic alterations with potential for therapeutic interventions.

Original languageEnglish
Pages (from-to)231-241
Number of pages11
JournalClinical and Translational Oncology
Volume8
Issue number4
DOIs
StatePublished - 2006

Fingerprint

Adenocarcinoma
Molecular Biology
Neoplasms
Microsatellite Instability
Mutation
DNA Mismatch Repair
Translational Medical Research
Gene Silencing
Endometrial Neoplasms
Tumor Biomarkers
Tumor Suppressor Genes
Diploidy
Karyotype
Oncogenes
Vascular Endothelial Growth Factor A
Therapeutics
Carcinoma
Phenotype
Bevacizumab

Keywords

  • Endometrial cancer
  • Genetic alterations
  • Molecular markers
  • New targets

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications. / Cerezo, Laura; Cárdenes, Higinia; Michael, Helen.

In: Clinical and Translational Oncology, Vol. 8, No. 4, 2006, p. 231-241.

Research output: Contribution to journalArticle

@article{7b022ca621324aebb333e4b83abca9c1,
title = "Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications",
abstract = "Molecular genetic evidence indicates that endometrial carcinoma likely develops as the result of a multistep process of oncogene activation and tumor suppressor gene inactivation. These molecular alterations appear to be specific for Type I (endometrioid) and Type II (non endometrioid) cancers. Type I cancers are characterized by mutation of PTEN, KRAS2, defects in DNA mismatch repair, as evidenced by the microsatellite instability phenotype, and a near diploid karyotype. Type II cancers often contain mutations of TP53 and Her-2/neu and are usually nondiploid. The clinical value of many of these molecular markers is now being tested and it may help to refine diagnosis and establish an accurate prognosis. Furthermore, some of these tumor biomarkers constitute the targets for emerging therapies. Transtuzumab against Her-2/neu and bevacizumab against VEGF overexpressing carcinomas are among the promising novel treatments. Additional translational research is needed to identify molecular and genetic alterations with potential for therapeutic interventions.",
keywords = "Endometrial cancer, Genetic alterations, Molecular markers, New targets",
author = "Laura Cerezo and Higinia C{\'a}rdenes and Helen Michael",
year = "2006",
doi = "10.1007/BF02664933",
language = "English",
volume = "8",
pages = "231--241",
journal = "Clinical and Translational Oncology",
issn = "1699-048X",
publisher = "Springer-Verlag Italia",
number = "4",

}

TY - JOUR

T1 - Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications

AU - Cerezo, Laura

AU - Cárdenes, Higinia

AU - Michael, Helen

PY - 2006

Y1 - 2006

N2 - Molecular genetic evidence indicates that endometrial carcinoma likely develops as the result of a multistep process of oncogene activation and tumor suppressor gene inactivation. These molecular alterations appear to be specific for Type I (endometrioid) and Type II (non endometrioid) cancers. Type I cancers are characterized by mutation of PTEN, KRAS2, defects in DNA mismatch repair, as evidenced by the microsatellite instability phenotype, and a near diploid karyotype. Type II cancers often contain mutations of TP53 and Her-2/neu and are usually nondiploid. The clinical value of many of these molecular markers is now being tested and it may help to refine diagnosis and establish an accurate prognosis. Furthermore, some of these tumor biomarkers constitute the targets for emerging therapies. Transtuzumab against Her-2/neu and bevacizumab against VEGF overexpressing carcinomas are among the promising novel treatments. Additional translational research is needed to identify molecular and genetic alterations with potential for therapeutic interventions.

AB - Molecular genetic evidence indicates that endometrial carcinoma likely develops as the result of a multistep process of oncogene activation and tumor suppressor gene inactivation. These molecular alterations appear to be specific for Type I (endometrioid) and Type II (non endometrioid) cancers. Type I cancers are characterized by mutation of PTEN, KRAS2, defects in DNA mismatch repair, as evidenced by the microsatellite instability phenotype, and a near diploid karyotype. Type II cancers often contain mutations of TP53 and Her-2/neu and are usually nondiploid. The clinical value of many of these molecular markers is now being tested and it may help to refine diagnosis and establish an accurate prognosis. Furthermore, some of these tumor biomarkers constitute the targets for emerging therapies. Transtuzumab against Her-2/neu and bevacizumab against VEGF overexpressing carcinomas are among the promising novel treatments. Additional translational research is needed to identify molecular and genetic alterations with potential for therapeutic interventions.

KW - Endometrial cancer

KW - Genetic alterations

KW - Molecular markers

KW - New targets

UR - http://www.scopus.com/inward/record.url?scp=33746814127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746814127&partnerID=8YFLogxK

U2 - 10.1007/BF02664933

DO - 10.1007/BF02664933

M3 - Article

VL - 8

SP - 231

EP - 241

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

SN - 1699-048X

IS - 4

ER -